%0 Journal Article
%A Palleis, Carla
%A Bernhardt, Alexander Maximilian
%A Weidinger, Endy
%A Fietzek, Urban M
%A Jäck, Alexander
%A Katzdobler, Sabrina
%A Gnoerich, Johannes
%A Bauer, Theresa
%A Franzmeier, Nicolai
%A Perneczky, Robert
%A Brendel, Matthias
%A Levin, Johannes
%A Höglinger, Günter U
%T A Biomarker-Based Classification of Corticobasal Syndrome.
%J Movement disorders
%V 41
%N 1
%@ 0885-3185
%C New York, NY
%I Wiley
%M DZNE-2026-00167
%P 129 - 142
%D 2026
%X Corticobasal syndrome (CBS) is a clinically defined syndrome with progressive movement and cortical dysfunction, caused by various underlying pathologies, most commonly tau-predominant pathologies such as progressive supranuclear palsy and corticobasal degeneration, or Alzheimer's disease (AD). Lewy-type α-synucleinopathies (LTS), TDP-43 proteinopathies, and mixed pathologies may also underlie CBS. The clinical impact of these pathologies remains poorly understood.To subclassify CBS patients in vivo using biomarkers for amyloid-β (Aβ), Tau, and α-synuclein (αSyn), and assess the clinical relevance of this stratification.We conducted a prospective cohort study of 50 CBS patients at LMU University Hospital Munich. Biomarker analysis included cerebrospinal fluid (CSF) Aβ42 and Aβ42/40, [18F]flutemetamol Aβ-PET, [18F]PI-2620 tau-PET, and αSyn seed amplification assays in CSF. CSF neurofilament light chain (NfL) served as a marker of neurodegeneration. Patients were stratified into six groups based on biomarker positivity.Tau positivity was found in 90
%K Humans
%K Male
%K Female
%K Aged
%K Biomarkers: cerebrospinal fluid
%K Amyloid beta-Peptides: cerebrospinal fluid
%K Middle Aged
%K tau Proteins: cerebrospinal fluid
%K Positron-Emission Tomography
%K alpha-Synuclein: cerebrospinal fluid
%K alpha-Synuclein: metabolism
%K Prospective Studies
%K Corticobasal Degeneration: classification
%K Corticobasal Degeneration: cerebrospinal fluid
%K Corticobasal Degeneration: diagnostic imaging
%K Peptide Fragments: cerebrospinal fluid
%K Aged, 80 and over
%K proteinopathies (Other)
%K tau‐PET (Other)
%K α‐synuclein seed amplification assay (Other)
%K β‐amyloid (Other)
%K Biomarkers (NLM Chemicals)
%K Amyloid beta-Peptides (NLM Chemicals)
%K tau Proteins (NLM Chemicals)
%K alpha-Synuclein (NLM Chemicals)
%K Peptide Fragments (NLM Chemicals)
%K amyloid beta-protein (1-42) (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41048081
%2 pmc:PMC12882055
%R 10.1002/mds.70070
%U https://pub.dzne.de/record/285043